Clinical Trials Browser

Phase 3 × Pathologic Complete Response × Azacitidine × Clear all

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 2 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute